Followers | 145 |
Posts | 27566 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, January 07, 2022 12:36:10 PM
https://www.nasdaq.com/articles/oramed-pharmaceuticals-updates-1-key-risk-factor
CONTRIBUTOR
Kailas Salunkhe TipRanks
PUBLISHED
JAN 6, 2022 2:59AM EST
Shares of oral drug delivery systems, Oramed Pharmaceuticals, Inc. (ORMP) have gained 180.3% over the past year. OMRP is focused on developing solutions for the treatment of diabetes, with two pipeline candidates - ORMD-0801 and ORMD-0901.
ORMD-0801 is being developed for treating diabetes and is currently under Phase-3 studies. Notably, ORMD-0801 can potentially become the first oral insulin capsule available commercially. Meanwhile, ORMD-0901 is targeted for type-2 diabetes.
Moreover, Oravax Medical, wherein Oramed is the largest shareholder, recently entered into a cooperation and purchase agreement with Vietnam’s Tan Thanh Holdings.
This agreement includes a 10 million dose pre-order of oral COVID-19 vaccines from Oravax (currently under development). Additionally, the two companies have agreed on potential follow-on orders.
With these developments in mind, let’s have a look at what’s changed in Oramed’s key risk factors that investors should know.
Risk Factors
According to the TipRanks Risk Factors tool, Oramed’s top risk category is Finance & Corporate, contributing 43% (compared to a sector average of 29%) to the total 35 risks identified. In its recent annual report, the company has added one key risk factor under the Finance & Corporate risk category.
Oramed noted that its current and any future joint ventures could limit the company’s flexibility with jointly owned investments. The risk also remains that Oramed may not achieve the expected benefits from such arrangements.
The possibility also remains that Oramed may have to contribute additional capital to the joint venture or that its partners may have other objectives, which could be inconsistent with Oramed’s goals.
Wall Street’s Take
On December 30, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on the stock, with a price target of $32 (170.5% upside potential).
Wall Street’s top analysts have a Strong Buy Consensus rating on Oramed based on 4 unanimous Buys. The average Oramed Pharmaceuticals price target of $34.25 implies a potential upside of 189.5%.
Recent ORMP News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:00:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:00:27 PM
- Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation • GlobeNewswire Inc. • 03/19/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 10:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:42:26 PM
- Oramed Letter to Shareholders • PR Newswire (US) • 02/20/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:45:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:43:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:41:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:40:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:39:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:37:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:36:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:34:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:33:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:32:23 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 06:13:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 02:26:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:45:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 08:34:25 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM